Pfizer edges up after better-than-expected quarterly results
BUZZ-Pfizer edges up after better-than-expected quarterly results ** Shares of drugmaker Pfizer PFE.N rise 0.8% to $25.26 premarket
** Co reports Q2 EPS of 77 cents/share, above analysts' expectations of 68 cents/share - LSEG data
** Posts Q2 sales of $15.03 bln, topping estimates of $14.41 bln
** Forecasts 2026 revenue at $60.5 bln to $62.5 bln, compared with prior view of $59.5 bln to $62.5 bln
** Says it expects an additional $2.5 bln in savings through its ongoing cost-cutting efforts, to be realized between 2027 and 2029
** "The near-term Pfizer story remains challenging given the multiple large patent expirations the company is facing, but we believe continued progress both commercially and with the pipeline should help increase investor interest in the name going forward," says Guggenheim analyst Vamil Divan
** As of last close, stock up 0.6% YTD
(Reporting by Kamal Choudhury in Bengaluru)
Recent news on Pfizer
See all newsBrief: Enanta Pharmaceuticals In Patent Infringement Action Against Pfizer
Brief: Edison Scientific Announces Agreement With Pfizer To Accelerate Research And Development
Bristol Myers raises 2026 revenue forecast, lowers EPS due to charge (updated)
Corrected: Bristol Myers raises 2026 revenue forecast, lowers EPS due to charge
Brief: Pfizer’S ELREXFIO Outperforms Standard Regimens And Meets Primary Endpoint In Phase 3 Study In Relapsed Or Refractory Multiple Myeloma